The characterisation of subjective cognitive decline

Frank Jessen; Rebecca E. Amariglio; Rachel F. Buckley; Wiesje M. van der Flier; Ying Han; José Luis Molinuevo; Laura Rabin; Dorene M. Rentz; Octavio Rodriguez-Gomez; Andrew J. Saykin; Sietske A.M. Sikkes; Colette M. Smart; Steffen Wolfsgruber; Michael Wagner

doi:10.1016/S1474-4422(19)30368-0

The characterisation of subjective cognitive decline

Frank Jessen^*, Rebecca E. Amariglio, Rachel F. Buckley, Wiesje M. van der Flier, Ying Han, José Luis Molinuevo, Laura Rabin, Dorene M. Rentz, Octavio Rodriguez-Gomez, Andrew J. Saykin, Sietske A.M. Sikkes, Colette M. Smart, Steffen Wolfsgruber, Michael Wagner

^*Corresponding author for this work

Clinical Neuropsychology

Research output: Contribution to Journal › Review article › Academic › peer-review

631 Downloads (Pure)

Abstract

A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline. An individually tailored diagnostic process might be reasonable to identify or exclude underlying medical conditions in an individual with SCD who actively seeks medical help. An increasing number of studies are investigating the link between SCD and the very early stages of Alzheimer's disease and other neurodegenerative diseases.

Original language	English
Pages (from-to)	271-278
Number of pages	8
Journal	The Lancet Neurology
Volume	19
Issue number	3
Early online date	17 Jan 2020
DOIs	https://doi.org/10.1016/S1474-4422(19)30368-0
Publication status	Published - Mar 2020

Funding

We declare no financial relationships directly related to this work. The following grants focus on the topic and results of this article, or support the author's related research: DZNE-DELCODE, BN012 (FJ); Medit-Ageing EU H2020, call PHC22 (FJ, JLM); AMYPAD EU-EFPIA IMI 2, grant 115952 (FJ, JLM); MOPEAD EU-EFPIA IMI 2, grant 115985 (FJ, ORG); EU JPND, Germany (BMBF grant 01ED1508 [FJ], the Netherlands [WMvdF]); SCIENCe project, Gieskes Strijbis Fonds (WMvdF); WMvdF holds the Pasman chair; Zon-MW Off Road, grant 451 001 010 (SAMS); Key Project, grant 61633018 (NSFC; YH); IH/NIA 1R01AG058825–01A1 (REA); National Institute on Aging , grants R01 AG019771 , P30 AG010133 , and U01 AG024904 (AJS). The following financial relationships outside of the presented work include the following: personal fees for advice from Eli Lilly, Biogen, MSD, Roche, Nutricia, and Janssen-Cilag, and grant support from Eli Lilly (FJ); grant support from Gieskes-Strijbis fonds, ZonMW, CVON, Pasman stichting, Biogen MA, Combinostics, NWO, EU-FP7, Piramal Neuroimaging, and Janssen-Stellar (WMvdF); personal fees for advice from Roche Diagnostics, Eisai, Oryzon, Roche, Biogen, and Novartis, and grant support from General Electric (JLM); fees for advice from Neurotrack and Eli Lilly (DMR); grant support from NIA (AJS); grant support from ZonMW Off Road (SAMS); fees for advice from Neurotrack and Eli Lilly (CMS); and REA, RFB, YH, LR, ORG, SW, and MW report no disclosures. We declare no financial relationships directly related to this work. The following grants focus on the topic and results of this article, or support the author's related research: DZNE-DELCODE, BN012 (FJ); Medit-Ageing EU H2020, call PHC22 (FJ, JLM); AMYPAD EU-EFPIA IMI 2, grant 115952 (FJ, JLM); MOPEAD EU-EFPIA IMI 2, grant 115985 (FJ, ORG); EU JPND, Germany (BMBF grant 01ED1508 [FJ], the Netherlands [WMvdF]); SCIENCe project, Gieskes Strijbis Fonds (WMvdF); WMvdF holds the Pasman chair; Zon-MW Off Road, grant 451 001 010 (SAMS); Key Project, grant 61633018 (NSFC; YH); IH/NIA 1R01AG058825?01A1 (REA); National Institute on Aging, grants R01 AG019771, P30 AG010133, and U01 AG024904 (AJS). The following financial relationships outside of the presented work include the following: personal fees for advice from Eli Lilly, Biogen, MSD, Roche, Nutricia, and Janssen-Cilag, and grant support from Eli Lilly (FJ); grant support from Gieskes-Strijbis fonds, ZonMW, CVON, Pasman stichting, Biogen MA, Combinostics, NWO, EU-FP7, Piramal Neuroimaging, and Janssen-Stellar (WMvdF); personal fees for advice from Roche Diagnostics, Eisai, Oryzon, Roche, Biogen, and Novartis, and grant support from General Electric (JLM); fees for advice from Neurotrack and Eli Lilly (DMR); grant support from NIA (AJS); grant support from ZonMW Off Road (SAMS); fees for advice from Neurotrack and Eli Lilly (CMS); and REA, RFB, YH, LR, ORG, SW, and MW report no disclosures.

Funders	Funder number
CVON
EU JPND
EU-FP7
Gieskes Strijbis Fonds	451 001 010
Gieskes-Strijbis Fonds
JLM
Piramal Neuroimaging
ZonMW Off Road
National Institute on Aging	P30AG010133, U01 AG024904, R01 AG019771
Division of Materials Research
Eli Lilly and Company
General Electric
Novartis
Roche
Biogen
Meso Scale Diagnostics
Horizon 2020 Framework Programme	115952, 115985, MOPEAD EU-EFPIA IMI 2, AMYPAD EU-EFPIA IMI 2
Cilag
National Natural Science Foundation of China	01A1, 1R01AG058825–01A1
ZonMw
Bundesministerium für Bildung und Forschung	01ED1508
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Shandong Academy of Medical Sciences	61633018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1474-4422(19)30368-0

The characterisation of subjective cognitive declineFinal published version, 837 KBLicence: Article 25fa Dutch Copyright Act

Persistent URL (handle)

Copy link address

Cite this

@article{4113b7f645ab4ba1b35010e319bdec1c,

title = "The characterisation of subjective cognitive decline",

abstract = "A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline. An individually tailored diagnostic process might be reasonable to identify or exclude underlying medical conditions in an individual with SCD who actively seeks medical help. An increasing number of studies are investigating the link between SCD and the very early stages of Alzheimer's disease and other neurodegenerative diseases.",

author = "Frank Jessen and Amariglio, {Rebecca E.} and Buckley, {Rachel F.} and {van der Flier}, {Wiesje M.} and Ying Han and Molinuevo, {Jos{\'e} Luis} and Laura Rabin and Rentz, {Dorene M.} and Octavio Rodriguez-Gomez and Saykin, {Andrew J.} and Sikkes, {Sietske A.M.} and Smart, {Colette M.} and Steffen Wolfsgruber and Michael Wagner",

year = "2020",

month = mar,

doi = "10.1016/S1474-4422(19)30368-0",

language = "English",

volume = "19",

pages = "271--278",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - The characterisation of subjective cognitive decline

AU - Jessen, Frank

AU - Amariglio, Rebecca E.

AU - Buckley, Rachel F.

AU - van der Flier, Wiesje M.

AU - Han, Ying

AU - Molinuevo, José Luis

AU - Rabin, Laura

AU - Rentz, Dorene M.

AU - Rodriguez-Gomez, Octavio

AU - Saykin, Andrew J.

AU - Sikkes, Sietske A.M.

AU - Smart, Colette M.

AU - Wolfsgruber, Steffen

AU - Wagner, Michael

PY - 2020/3

Y1 - 2020/3

N2 - A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline. An individually tailored diagnostic process might be reasonable to identify or exclude underlying medical conditions in an individual with SCD who actively seeks medical help. An increasing number of studies are investigating the link between SCD and the very early stages of Alzheimer's disease and other neurodegenerative diseases.

AB - A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline. An individually tailored diagnostic process might be reasonable to identify or exclude underlying medical conditions in an individual with SCD who actively seeks medical help. An increasing number of studies are investigating the link between SCD and the very early stages of Alzheimer's disease and other neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=85079417063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079417063&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(19)30368-0

DO - 10.1016/S1474-4422(19)30368-0

M3 - Review article

C2 - 31958406

AN - SCOPUS:85079417063

SN - 1474-4422

VL - 19

SP - 271

EP - 278

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 3

ER -

The characterisation of subjective cognitive decline

Abstract

Funding

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this